Inclusion Criteria:

- Histological or cytological confirmed pancreatic cancer.

- Not eligible for curative resection.

- No distant metastases present.

- Previously untreated with chemotherapy and anti-cancer biologicals for current
malignancy.

- No other current malignant disease, except for basal cell carcinoma of the skin.

- Measurable or evaluable disease as defined by RECIST 1.1 criteria.

- Performance status 0-2 Eastern Cooperative Oncology Group (ECOG) Performance Status
(PS) Scale.

- Age ≥ 18 years.

- Adequate haematological and biological functions:

- Bone marrow function:

1. Neutrophils ≥ 1.5 x 109/L

2. Platelets ≥ 100 x 109/L

3. Hb ≥ 6 mmol/L

- Hepatic function:

1. AST/ALT and alkaline phosphatase (ALP) ≤ 2.5 x institutional upper limit of
normal (ULN)

2. Bilirubin ≤ 1.5 times institutional ULN

- Renal function:

eGFR >50ml/min

• Metabolic Function:

1. Magnesium ≥ lower limit of normal

2. Calcium ≥ lower limit of normal.

- No imminent bowel obstruction.

- No active bleeding.

- No uncontrolled infection.

- Patients with reproductive potential must use effective contraception. Female
patients must have a negative pregnancy test.

- Signed informed consent.

Exclusion Criteria:

- Participation in another therapeutic clinical study within 30 days of enrollment or
during this clinical study.

- No adequate radiation therapy possible: based on the opinion of the radiation
oncologist when radiation therapy cannot be performed because radiation field is too
large (PTV volume too large or OAR too high)

- History of allergic reactions to gemcitabine or antibody treatment.

- Presence of any serious concomitant systemic disorders incompatible with the clinical
study (e.g. uncontrolled inter-current illness including ongoing or active infection,
uncontrolled hypertension).

- Clinically significant cardiovascular disease (including myocardial infarction,
unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac
arrhythmia) within 1 year before enrolment/randomization

- History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or
evidence of interstitial lung disease on baseline chest CT scan

- Presence of any significant central nervous system or psychiatric disorder(s) that
would hamper the patient's compliance.

- Pregnant or breastfeeding women.

- Absence of adequate contraception for both male and female fertile patients for the
duration of the study; and also for six months after last treatment.

- Known positive status for HIV and/or hepatitis B or C.

- Any reason why, in the investigator's opinion, the patient should not participate in
the study.

- Drug or alcohol abuse.